SECTION I

BIOTHREATS AND EMERGING INFECTIOUS DISEASES
CHAPTER 1

Agents of Emerging Infectious Diseases

Juan P. Olano and David H. Walker
Departments of Pathology and Microbiology and Immunology, Center for Biodefense and Emerging Infectious Diseases, Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX, USA

OUTLINE

Introduction
Emerging Infectious Diseases Since 1967
Emerging Infections Causing Acute Respiratory Infections
Viral Pulmonary Syndromes
Influenza viruses
Severe acute respiratory syndrome (SARS)
Human metapneumovirus
Hantavirus cardiopulmonary syndrome (HCPS)
Bacterial Pulmonary Syndromes
Legionnaires’ disease
Tuberculosis
Viral hemorrhagic fevers (VHF)
Rift Valley fever (RVF)
Ebola hemorrhagic fever (EHF)
South American hemorrhagic fevers
Dengue fever
Emerging Encephalitic Syndromes
Nipah virus infection
West Nile virus (WNV) infection
Prion diseases (transmissible neurodegenerative diseases)

Arthropod Transmitted Bacterial Diseases
Lyme borreliosis (Lyme disease)
Rickettioses
Ehrlichioses and anaplasmosis
Scrub typhus
Bartonelloses

Emerging Enteric Pathogens
Cholera
Nontyphoidal salmonellosis
Shiga-toxin producing Escherichia coli infection
Helicobacter pylori infection
Cryptosporidiosis
Microsporidioses

Other Emerging Bacterial Pathogens
Diphtheria
Bordetella infections
Staphylococcus aureus infections

Group A β-Hemolytic Streptococcal (GABHS) Infections
Streptococcus pyogenes infections
Streptococcus agalactiae infections
ABSTRACT

Dramatic improvements in the control of infectious diseases in developed countries owing to socioeconomic changes, vaccines, and antibiotics during the first seven decades of the 20th century led to the mistaken concept that infectious diseases would no longer be a concern. Since the declaration of victory in the war against infectious diseases in 1967, approximately 50 new disease agents have been identified. Nearly every type of etiologic agent and clinical manifestation have been involved including acute respiratory infections (e.g., H5N1 influenza A, SARS, hantaviral cardiopulmonary syndrome, and Legionnaires’ disease), central nervous system involvement (e.g., West Nile encephalitis, Nipah virus encephalitis, and prion diseases), enteric infections (e.g., *Helicobacter pylori* gastric and duodenal diseases, cryptosporidiosis, microsporidioses, and Shiga toxin diseases), systemic bacterial diseases (e.g., Lyme disease, six new rickettsioses, three new human ehrlichioses, bartonelloses, and staphylococcal and streptococcal toxic shock syndrome), viral hemorrhagic fevers (e.g., Marburg, Ebola, Lassa, Bolivian, Argentine, and Venezuelan hemorrhagic fevers), human retroviral infections (e.g., HIV1 and 2 and HTLV-I and II), new human herpesviruses (HHV6, HHV7, and HHV8), and the viral agents of hepatitis A, B, C, D, and E.

There are the reciprocal threats that a bioterror agent (e.g., smallpox virus) could cause a newly emerging infectious disease (EID) and that an agent of emerging infections (e.g., SARS-coronavirus or Rift Valley fever virus) could be disseminated by terrorists.

Vaccines offer a critically important potential countermeasure against the effects of these and future EIDs. An aggressive approach to developing prototype vaccines against each new class of etiologic agent must be driven by public health initiatives because commercial interests will not undertake these projects. The microbe must be completely characterized biologically, molecularly, and genetically. An accurate animal model of the human infectious disease should be developed. The mechanisms of vaccine-induced protective immunity must be elucidated and the antigens that stimulate these mechanisms of protective immune memory identified. Preclinical testing of vaccine candidates should then be completed in the animal models.

It would be most effective if subunit vaccine platforms were developed in which new antigen cassettes could be inserted and FDA approval obtained using one or more prototypes. Experience in manufacturing and a track record of effectiveness and safety for vaccines against numerous emerging infectious agents could be achieved for veterinary diseases caused by organisms that also cause emerging human infections (e.g., West Nile virus and ehrlichioses).

In the United States, these approaches are driven currently by individual investigator initiative in pursuing the scientific questions through grants from the National Institute of Allergy and Infectious Diseases. Progress occurs, but not at the desired level. An emerging infection with high transmissibility (e.g., $R_0 = 10$) and a case-fatality rate of 15% would cause global devastating effects at a level on the order of magnitude of a nuclear war. Our efforts to prepare for EIDs fall far short of nuclear attack preparedness during the Cold War.

INTRODUCTION

A rather optimistic statement in 1967 from the US Surgeon General proclaimed that “the war against infectious diseases has been won.” The emergence and re-emergence of infectious diseases during the past four decades has been astounding and has obviously proved this highly publicized statement wrong. A former director of the National Institute of Allergy and Infectious Diseases stated in 1981 that microbial diversity and evolutionary vigor were still dynamic forces threatening mankind. With the advent of revolutionary research tools, our view of the world of microbial diversity continues to expand.
respiratory tract infections. Upper respiratory tract infections, although important from the point of view of morbidity, are rarely fatal. In developed countries the main culprits are influenza and bacterial pneumonia. In underdeveloped countries, the highest mortality rates are seen in children less than 5 years of age with viral pneumonia caused by respiratory syncytial virus, parainfluenza viruses, influenza viruses, and adenoviruses. Bacterial respiratory agents include Streptococcus pneumoniae, Hemophilus influenzae, and Staphylococcus aureus.

EMERGING INFECTIOUS DISEASES SINCE 1967

We have attempted to create a comprehensive list of infectious diseases that fall into this category (Table 1.1). A discussion of the clinico-epidemiological characteristics of the most representative emerging infectious diseases (EIDs) follows. We have classified EIDs based on clinical presentation (syndromes such as pneumonia, encephalitis, systemic bacterial infection, enteric infection, and viral hemorrhagic fever).

EMERGING INFECTIONS CAUSING ACUTE RESPIRATORY INFECTIONS

Acute respiratory infections are the leading cause of mortality from infectious diseases around the world. In 2003, 37 million deaths were due to acute lower respiratory tract infections. Upper respiratory tract infections, although important from the point of view of morbidity, are rarely fatal. In developed countries the main culprits are influenza and bacterial pneumonia. In underdeveloped countries, the highest mortality rates are seen in children less than 5 years of age with viral pneumonia caused by respiratory syncytial virus, parainfluenza viruses, influenza viruses, and adenoviruses. Bacterial respiratory agents include Streptococcus pneumoniae, Hemophilus influenzae, and Staphylococcus aureus.

VIRAL PULMONARY SYNDROMES

Influenza Viruses

These viruses belong to the family Orthomyxoviridae and are enveloped, negative sense, single-stranded, segmented, RNA viruses responsible for recurrent epidemics of febrile respiratory disease every 1–2 years. Influenza viruses are further classified as A, B, and C based on antigenic characteristics. Influenza B and C viruses only undergo antigenic drift as compared with influenza A viruses that can undergo antigenic shift in addition to antigenic drift. Antigenic shifts are responsible for the major pandemics seen with influenza A viruses, three of which occurred in the 20th century, including the highly lethal 1918/1919 pandemic that killed tens of millions of people around the world. Pandemics do not occur with influenza B and C viruses. In fact influenza C causes a mild disease without seasonality, and influenza B causes severe disease confined to the elderly and other persons at high risk. Influenza A viruses are divided into subtypes based on the presence of different hemagglutinin (H) and neuraminidase (N) molecules on their surface. Sixteen distinct hemagglutinins and nine different neuraminidases have been described to date. Influenza viruses are among the most contagious human viruses with attack rates of 10–40% during epidemics. Epidemics are seasonal (winter) in temperate regions and can occur year round in tropical areas. Since the last influenza pandemic in 1968, the predominant virus circulating around the world is the H3N2 subtype that undergoes minor mutations in the H and N proteins and is responsible for yearly outbreaks. In 1977, the H1N1 virus (the same subtype that was responsible for the 1918 pandemic) was reintroduced and is currently co-circulating with H3N2 virus. However, isolated cases of human influenza due to avian viruses such as H5N1 are cause for concern among health professionals around the world because of the high lethality and the possibility that development of efficient
TABLE 1.1  Infectious diseases with agents identified since “The end of the war against infectious diseases” 1967–2004

<table>
<thead>
<tr>
<th>Year</th>
<th>Agent</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>1967</td>
<td>Marburg virus</td>
<td>Marburg hemorrhagic fever</td>
</tr>
<tr>
<td>1969</td>
<td>Lassa virus</td>
<td>Lassa fever</td>
</tr>
<tr>
<td>1971</td>
<td>JC virus</td>
<td>Progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>1972</td>
<td>Norovirus</td>
<td>Norwalk diarrheal illness</td>
</tr>
<tr>
<td>1973</td>
<td>Rotavirus</td>
<td>Major cause of infantile diarrhea worldwide</td>
</tr>
<tr>
<td>1975</td>
<td>Parvovirus B19</td>
<td>Fifth disease; aplastic crisis in chronic hemolytic anemia; hydrops fetalis; chronic anemia of immunosuppressed patient</td>
</tr>
<tr>
<td>1976</td>
<td>Vibrio vulnificus</td>
<td>Sepsis and necrotizing fascitis</td>
</tr>
<tr>
<td>1976</td>
<td>Cryptosporidium parvum</td>
<td>Human cryptosporidiosis</td>
</tr>
<tr>
<td>1977</td>
<td>Ebola virus</td>
<td>Ebola hemorrhagic fever</td>
</tr>
<tr>
<td>1977</td>
<td>Clostridium difficile</td>
<td>Pseudomembranous colitis</td>
</tr>
<tr>
<td>1977</td>
<td>Legionella pneumophila</td>
<td>Legionnaires' disease, Pontiac fever</td>
</tr>
<tr>
<td>1977</td>
<td>Hantaan virus</td>
<td>Hemorrhagic fever with renal syndrome</td>
</tr>
<tr>
<td>1977</td>
<td>Delta viral hepatitis</td>
<td>Hepatitis B virus-associated hepatitis</td>
</tr>
<tr>
<td>1977</td>
<td>Campylobacter sp.</td>
<td>Enteric pathogens distributed globally</td>
</tr>
<tr>
<td>1977</td>
<td>Vibrio parahaemolyticus</td>
<td>Diarrheal illness</td>
</tr>
<tr>
<td>1977</td>
<td>Cryptosporidium parvum</td>
<td>Human cryptosporidiosis</td>
</tr>
<tr>
<td>1979</td>
<td>Cyclospora cayetanensis</td>
<td>Diarrheal illness</td>
</tr>
<tr>
<td>1980</td>
<td>HTLV-I</td>
<td>T-cell lymphoma-leukemia; tropical spastic paresis</td>
</tr>
<tr>
<td>1981</td>
<td>Staphylococcus aureus toxin</td>
<td>Toxic shock syndrome</td>
</tr>
<tr>
<td>1982</td>
<td>Borrelia burgdorferi</td>
<td>Lyme disease</td>
</tr>
<tr>
<td>1982</td>
<td>Escherichia coli 0157:H7</td>
<td>Hemorrhagic diarrhea, hemolytic uremic syndrome</td>
</tr>
<tr>
<td>1982</td>
<td>HTLV-II</td>
<td>Associated with neurologic syndromes</td>
</tr>
<tr>
<td>1983</td>
<td>HIV-1</td>
<td>AIDS</td>
</tr>
<tr>
<td>1983</td>
<td>Helicobacter pylori</td>
<td>Gastric and duodenal ulcers</td>
</tr>
<tr>
<td>1984</td>
<td>Hemophilus influenzae aegyptius</td>
<td>Brazilian purpuric fever</td>
</tr>
<tr>
<td>1985</td>
<td>Enterocytozoon bieneusi</td>
<td>Microsporidiosis</td>
</tr>
<tr>
<td>1986</td>
<td>Chlamydia pneumoniae</td>
<td>A major cause of pneumonia</td>
</tr>
<tr>
<td>1988</td>
<td>Human herpesvirus 6</td>
<td>Exanthem subitum (roseola infantum)</td>
</tr>
<tr>
<td>1989</td>
<td>Rickettsia japonica</td>
<td>Japanese spotted fever</td>
</tr>
<tr>
<td>1989</td>
<td>Hepatitis C virus</td>
<td>Parenterally transmitted nonA-nonB hepatitis</td>
</tr>
<tr>
<td>1990</td>
<td>Hepatitis E virus</td>
<td>Enteric nonA, nonB hepatitis</td>
</tr>
<tr>
<td>1990</td>
<td>Balamuthia mandrillaris</td>
<td>Leptomyxid amebic meningoecephalitis</td>
</tr>
<tr>
<td>1990</td>
<td>Human herpesvirus 7</td>
<td>Another cause of exanthem subitum</td>
</tr>
<tr>
<td>1991</td>
<td>Guanarito virus</td>
<td>Venezuelan arenaviral hemorrhagic fever</td>
</tr>
<tr>
<td>1991</td>
<td>Encephalitozoon hellem</td>
<td>Microsporidiosis</td>
</tr>
<tr>
<td>1991</td>
<td>Ehrlichia chaffensis</td>
<td>Human monocytotropic ehrlichiosis</td>
</tr>
<tr>
<td>1992</td>
<td>Barmah Forest virus</td>
<td>Febrile polyarthralgia</td>
</tr>
<tr>
<td>1992</td>
<td>Vibrio cholerae 0139</td>
<td>New strain associated with epidemic cholera</td>
</tr>
<tr>
<td>1992</td>
<td>Bartonella henselae</td>
<td>Cat scratch disease; bacillary angiomatosis; endocarditis</td>
</tr>
<tr>
<td>1992</td>
<td>Rickettsia honei</td>
<td>Flinders Island spotted fever</td>
</tr>
<tr>
<td>1992</td>
<td>Tropheryma whippelii</td>
<td>Whipple’s disease</td>
</tr>
<tr>
<td>1993</td>
<td>Sin Nombre hantavirus</td>
<td>Hantavirus cardiopulmonary syndrome</td>
</tr>
<tr>
<td>1994</td>
<td>Anaplasma phagocytophilium</td>
<td>Human granulocytic anaplasmosis</td>
</tr>
<tr>
<td>1994</td>
<td>Hendra virus</td>
<td>Acute respiratory syndrome, meningitis</td>
</tr>
<tr>
<td>1996</td>
<td>Human herpesvirus 8</td>
<td>Kaposi’s sarcoma, Castleman’s disease, primary effusion based B-cell lymphoma</td>
</tr>
</tbody>
</table>
TABLE 1.1 (Continued)

<table>
<thead>
<tr>
<th>Year</th>
<th>Agent</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997</td>
<td>Rickettsia slovaca</td>
<td>Tick-borne lymphadenopathy</td>
</tr>
<tr>
<td>1999</td>
<td>Ehrlichia ewingii</td>
<td>Ehrlichiosis ewingii</td>
</tr>
<tr>
<td>1999</td>
<td>Nipah virus</td>
<td>Encephalitis</td>
</tr>
<tr>
<td>2001</td>
<td>Human metapneumovirus</td>
<td>Upper and lower respiratory infections</td>
</tr>
<tr>
<td>2003</td>
<td>SARS-CoV</td>
<td>Severe acute respiratory syndrome (SARS)</td>
</tr>
<tr>
<td>2004</td>
<td>Monkeypox virus</td>
<td>Human monkeypox (USA outbreak)</td>
</tr>
</tbody>
</table>

person-to-person transmission could trigger another pandemic. The first case of human influenza due to H5N1 was described in 1997, and the infection re-emerged in Southeast Asia in 2004. Death rates in domestic birds in Southeast Asia are staggering. Other avian influenza viruses have also emerged in other parts of the world such as H7N7 in the Netherlands causing an outbreak of hemorrhagic conjunctivitis in humans. Influenza A viruses are capable of infecting a wide variety of animals including birds, horses, marine mammals, swine, and humans. The most important reservoir is wild aquatic birds (water fowl, ducks, and shorebirds). These animals can carry different subtypes in their gut, and some viruses are capable of infecting domestic poultry. The ability of avian influenza viruses to infect humans is rather restricted as is the ability for transmission from person-to-person. Because of their segmented genomes, influenza A viruses have the potential to swap or re assort genes when present in the same host or “mixing vessel” such as pigs (these animals have cell surface receptors that allow cellular entry of both bird and human influenza viruses). If the favorable environmental conditions are present, human influenza viruses can coexist with avian viruses in pigs, and new reassortants may be produced with potentially enhanced ability to infect humans.

Clinically, the human disease manifests as a severe febrile illness with abrupt onset, myalgias, severe malaise, dry cough, arthralgias and nasal discharge. Most patients recover from the acute phase of the disease in 3–5 days. Complications include primary influenza viral pneumonitis, which was first well documented in the 1957–1958 pandemic. However, it is widely accepted that this and bacterial superinfections were the causes of death of millions of persons in the 1918 pandemic. These patients progress to acute respiratory failure rapidly, and the main pathologic finding is that of diffuse alveolar damage with a hemorrhagic component. Other complications include secondary bacterial pneumonias.

Severe Acute Respiratory Syndrome (SARS)

An explosive outbreak of severe adult respiratory distress syndrome (ARDS) occurred in residents of Hong Kong and persons who had visited Hong Kong early in 2003. A cluster of cases that had started in November 2002 also occurred in the Guangdong Province of China. After a few months of excellent “detective” work by health agencies and research laboratories worldwide, a new coronavirus was identified as the culprit. Between November 2002 and July 2003, 8096 cases were reported from nearly 30 countries, but the vast majority of cases occurred in mainland China and Hong Kong. The case-fatality rate was between 7 and 17% and approached 50% in the elderly. High mortality rates were also observed in patients with preexisting conditions such as diabetes and cardiopulmonary diseases.

An animal reservoir for SARS-CoV appears likely to be bats, but the virus also has been isolated from civet cats and other wild animals in markets in China where cross-species infections may have occurred. Other coronaviruses in humans have cyclical patterns of circulation. It is suspected that SARS-CoV could reappear in humans. In severe cases, the main finding is diffuse alveolar damage leading to acute respiratory insufficiency. In milder cases, fever, malaise and myalgia are the main manifestations.

Human Metapneumovirus

This viral pathogen was first identified in 2001 in an outbreak of upper and lower respiratory illness in the Netherlands. The agent is a paramyxovirus, subfamily Pneumovirinae in which two genera have been established: Pneumovirus (respiratory syncytial virus, RSV) and Metapneumovirus. The disease spectrum is not completely known but can manifest as severe upper and lower respiratory infections in children and adults especially in patients with previous cardiopulmonary conditions. The disease is similar to RSV.
infection and can account for up to 10% of acute upper respiratory tract infections in which another etiologic agent has not been identified. Asthmatic exacerbations have also been related to metapneumovirus infections. Retrospective serological studies have established that this virus has been circulating in humans for at least 50 years.

Hantavirus Cardiopulmonary Syndrome (HCPS)

Sin Nombre virus (SNV) was the first hantavirus in the Americas associated with HCPS. The disease was first described in an outbreak in the Four Corners area of the southwestern US in 1993. SNV belongs to the genus Hantavirus within the family Bunyaviridae. The vast majority of viruses within this family are arthropod-borne zoonoses, with the exception of hantaviruses, which are not vector-borne. Hantaviruses are found in wild rodents, which excrete the virus in urine and saliva for months. SNV is the most important pathogenic hantavirus in North America and causes chronic infections in deer mice (Peromyscus maniculatus). In North America, other viruses within the same genus associated with HCPS have been described such as New York virus found in the white footed deer mouse (Peromyscus leucopus). In South America, the main representative of the genus is Andes virus, which is responsible for HCPS in Chile and Argentina, and is the only hantavirus for which human-to-human transmission has been documented. In 1978, another hantavirus associated with hemorrhagic fever and renal syndrome (HFRS) in the Korean peninsula was isolated. This infection is endemic across the Asian continent.

The main mode of transmission is through aerosol spread of infected excreta (urine and possibly feces) and less frequently by bites of infected rodents. HCPS is an explosive febrile illness accompanied by myalgias and sometimes abdominal pain. In 4–5 days, respiratory symptoms appear and rapidly progress to severe noncardiogenic pulmonary edema with subsequent hypoxia and shock within hours. Cardiac dysfunction also occurs.

BACTERIAL PULMONARY SYNDROMES

Legionnaires’ Disease

An outbreak of pneumonia in 1976 in Philadelphia, Pennsylvania during the state American Legion convention affected 221 people, 34 of whom died from the infection. In 1977, Dr. McDade and Dr. Shepard at the CDC isolated the etiologic agent, a fastidious gram negative organism later named Legionella pneumophila. This bacterium has been responsible for subsequent epidemics and sporadic cases, and retrospective studies determined that it had been responsible for outbreaks of pneumonia in the 1950s and 1960s. Legionella species are naturally occurring aquatic bacteria that grow in warm water, especially in cooling towers, water heaters and plumbing, hence the propensity to cause nosocomial and community outbreaks (hotels and other facilities). Free-living amebas also support the intracellular growth of Legionella spp. More than 20 Legionella species have been described affecting humans, thus the general name of legionellosis.

The disease occurs both sporadically (65–75% of cases) and in outbreaks or epidemics. Recent epidemics have occurred in Spain (2001, 700 cases), England (2002, 130 cases), and the Netherlands (1999, 188 cases).

Transmission is by aerosolization of contaminated water sources. Once in the alveoli of the lung, the bacteria are phagocytosed by alveolar macrophages through phagocytosis, and multiplication occurs. The bacteria are then released into the alveolar space by dying macrophages where they can invade other alveolar macrophages. A type IV secretion system is important in promoting intracellular infection including inhibition of phagolysosomal fusion. The lungs reveal patchy-to-confluent bronchopneumonia that may be complicated by pleural effusions or cavitation in a minority of cases. Extrapulmonary infection is rare.

Tuberculosis

Tuberculosis (TB) is as old as civilization itself as demonstrated by evidence of spinal tuberculosis in Egyptian mummies and Neolithic and pre-Columbian bones. However, tuberculosis did not become a major public health problem until the 17th and 18th centuries during the Industrial Revolution. Tuberculosis also ravaged (and still does) the native American populations after Columbus’ voyages to the Americas. In the United States, tuberculosis saw a steady decline in the middle part of the 20th century until 1985 when the incidence climbed again principally due to the appearance of HIV. Other factors included deterioration of living conditions, intravenous drug abuse, and under-funding of tuberculosis control programs. However, since the mid-1990s rates have declined and in 2002 reached the lowest incidence in history from the time statistics became available. This control is the result of better anti-HIV therapies, intensified diagnosis, aggressive and monitored anti-TB treatment and prevention efforts. However, not all is good news in
the TB world. The appearance of multidrug resistant strains of *M. tuberculosis* is a challenge recalling the preantibiotic era. In addition, *M. tuberculosis* is the number one killer worldwide (2 million deaths and 8 million new cases diagnosed each year), and approximately 2 billion people are infected.

More than 95% of infections caused by *M. tuberculosis* are acquired by inhalation of aerosols generated from an infectious patient. The initial focus of infection (Gohn's lesion) later develops into Gohn's complex (accompanying infected draining hilar lymph node lesions), and in most cases the infection is contained by the immune system. In the most severe cases, the infection disseminates hematogenously in the lungs and/or systemically leading to miliary tuberculosis. Individuals who control the primary infection may undergo reactivation of the latent infection due to multiple factors including AIDS, malnourishment, alcoholism, and cancer. In these cases, reactivation can involve the lungs (cavitary, endobronchial, pneumonic, and/or bronchopneumonic) and other organs including the spleen, liver, bone marrow, kidneys, CNS, and bones. Primary and secondary mycobacterial resistance to antituberculosis medication in certain subpopulations in New York City and California makes tuberculosis a public health priority. Recent trends have shown that the percentage of isolates with resistance to antituberculosis drugs is decreasing due to vigorous public health efforts.

Viral Hemorrhagic Fevers (VHF)

It is estimated that 75% of EIDs in humans originate in animals, and VHF s are remarkable examples. The etiologic agents of this syndrome are a heterogeneous group of RNA viruses belonging to three families, namely filoviruses (Ebola and Marburg viruses), arenaviruses (Lassa, Junin, Machupo, Guanarito, and Sabia viruses), and bunyaviruses (Crimean-Congo hemorrhagic fever and Rift Valley fever (RVF) viruses).

All these viruses have limited geographic ranges due to their specific natural reservoirs and vectors. In all cases, humans are accidental hosts. Pathogenetically, all VHF s lead to dramatically increased vascular permeability systemically with a hemorrhagic diathesis and edema in multiple organ systems, including the lungs and brain. These diseases all occur in localized outbreaks usually with very high case-fatality rates. Clinically, subtle differences exist between the syndromes such as more prominent hemorrhagic manifestations and terminal disseminated intravascular coagulation (DIC) in infections caused by filoviruses and CCHF, and prominent CNS and hemorrhagic manifestations in infections by the New World arenaviruses (Junin, Machupo, Sabia, and Guanarito), and prominent liver disease in RVF.

Rift Valley Fever

This is a mosquito-borne viral disease that affects newborn ruminants, especially sheep. Other affected animals include lambs, calves, goats, kittens, mice, and hamsters. The virus was first isolated in 1930 from sheep in Kenya, and the known distribution was limited to the African continent for decades. However, in 2000, a large epidemic in the Arabian peninsula led to high case-fatality ratios in humans, which had usually been around 5% in previous epidemics. Complications include hepatorenal failure, encephalitis and DIC leading to shock and multiorgan failure. The vector range for the virus is impressive and includes at least 30 species of mosquitoes in eight genera. Transovarial transmission occurs in the mosquitoes. Most outbreaks are related to climatic events that favor floods leading to increased vector populations. Outbreaks in Africa, besides the original one in Kenya, have occurred in Egypt (Aswan Dam construction), Mauritania in 1987 (Diama Dam construction), Kenya and Somalia in 1997–1998 (increased rainfall due to El Niño oscillation), and Kenya in 2007.

Ebola Hemorrhagic Fever (EHF)

Close to 20 outbreaks have occurred in Africa since Ebola virus was identified in 1976 in central Africa. The reservoir has been elusive although human outbreaks are usually preceded by severe primate die-offs. Recent studies of animals in the areas of primate mortality have identified bats as a likely reservoir host. Primary mechanisms of transmission from nonhuman primates to humans include contact with dead carcases or handling or consumption of bushmeat. The virus has also been linked to lethal outbreaks in duikers, a wild ruminant. Other factors associated with EHF outbreaks include increases in rainfall. The viruses are rather stable genetically, since isolates obtained 20 years apart have limited genetic variation. The disease is rapidly progressive and leads to hemorrhagic manifestations very quickly.

South American Hemorrhagic Fevers

South American hemorrhagic fevers (HF) are caused by arenaviruses whose geographic distribution is limited. Most arenaviruses in Africa and the Americas do not cause human disease. Rodents develop a chronic infection that is most times asymptomatic but with...
Nipah Virus Infection

This agent is a recently discovered paramyxovirus that, along with Hendra virus, comprises a new genus (*Henipavirus*) in the family Paramyxoviridae. In 1999, an outbreak of an acute febrile encephalitic syndrome in Malaysia was traced to Nipah virus. The epidemic was preceded by an epizootic of severe respiratory disease in pigs that was terminated after epidemiological control measures were instituted, including the culling of millions of pigs. A total of 283 cases of human encephalitis were diagnosed with a case-fatality rate close to 40%. A relapsing/remitting neurologic syndrome has also been associated with Nipah virus. A subsequent outbreak occurred in Bangladesh, but swine were not associated with this event, suggesting different ecological factors. The natural reservoir is thought to be fruit bats of the *Pteropus* genus. Other animals such as dogs, cats, and horses could also serve as hosts.

Hendra virus was first described in 1994 in Australia during a highly lethal epidemic of acute respiratory disease in horses. The only two human cases that have been associated with Hendra viruses manifested as acute respiratory syndrome and leptomenigitis, respectively. Both cases were fatal. The natural reservoir for Hendra virus is the fruit bat.

West Nile Virus (WNV) Infection

WNV was first isolated from humans in 1939 in Uganda and remained limited to the Middle East, Eastern Europe, and Africa until 1999, when an outbreak occurred in New York. By 2002, WNV spread across North America to the west coast, and annual outbreaks are now the rule. In 2002 and 2003, approximately 4000 and 9000 (case definition was modified in 2003) cases occurred, respectively, leading to CNS disease in 3000 and 2700 cases each year, respectively. Previous outbreaks of West Nile fever have occurred in Israel (1957), South Africa (1974), Algeria (1994), Tunisia (1997), and Congo (1998). WNV circulates enzootically between birds and mosquitoes. At least 300 species of birds and 62 species of mosquitoes can be infected by WNV. Most susceptible birds are the *Corvidae* (blue jays and crows), and the most important mosquito in the enzootic cycle is *Culex pipiens*. Humans and horses are dead-end hosts, both developing febrile and/or encephalitic syndromes. Other forms of transmission are through transplanted organs, transfusion, and breast milk. In fact, blood testing by PCR is now a component of the screening process for donated blood.

Prion Diseases (Transmissible Neurodegenerative Diseases)

Initially known as “atypically slow infections” (Sigurdsson, 1954), the concept of prion (proteinaceous...
infectious agents) was first introduced by Prussiner in 1982. Currently a prion is known as “a small infectious pathogen that contains protein and is resistant to procedures that modify or hydrolyze nucleic acids.” The pathogenesis of these diseases involves the generation and accumulation of abnormal prion protein from a normal isoform. The common denominator in these diseases is the presence of progressive neuronal degeneration (incubation periods measured in years or decades) accompanied by reactive astrocytosis and absence of inflammation. In most cases, prominent vacuolation of cells or neuropil is observed microscopically. Accumulation of abnormal prions in CNS tissue is present in all cases.

In humans, prions are responsible for several diseases of which Creutzfeldt-Jakob disease (CJD) and its new variant (linked to “mad cow disease” or bovine spongiform encephalopathy) are the most common. Other diseases include kuru, familial fatal insomnia (FFI), and Gerstmann–Straussler–Scheinker syndrome (GSS). CJD has several forms including sporadic (source of infection unknown), familial (mutations in the PrP gene), and iatrogenic (cadaveric grafts from patients with CJD). Kuru was related to anthropopagic practices in isolated tribes in Papua New Guinea, and new variant CJD has been linked to BSE. GSS and FFI are due to genetic mutations in the PrP gene in most cases.

**ARTHROPOD TRANSMITTED BACTERIAL DISEASES**

**Lyme Borreliosis (Lyme Disease)**

Lyme borreliosis is a zoonosis transmitted by hard ticks of the genus *Ixodes*. The vector in the eastern United States is *Ixodes scapularis* and in the western United States is *Ixodes pacificus*. *Ixodes ricinus* is the vector in Europe whereas *Ixodes persulcatus* is the vector in Russia and northern Asia. *B. burgdorferi* sensu lato includes *Borrelia burgdorferi* sensu stricto, *B. afzelii*, and *B. garinii*. The latter two are responsible for most cases of Lyme borreliosis in Europe, Russia, and northern Asia. Lyme disease has not been documented in tropical areas. The main hosts of *B. burgdorferi* in nature are rodents. Larval forms of ticks acquire the infection from small mammals, and the spirochetes are transmitted transstadially to nymphal and adult ticks. Human infections usually occur secondarily to nymph bites that go unnoticed very easily due to their small size.

Lyme borreliosis is a disease with an acute phase characterized by erythema migrans and nonspecific symptoms such as fever, headaches, myalgias, and arthralgias. The chronic phase (weeks to years) is characterized by oligoarthritis, central and peripheral nervous system sequelae, myocarditis, and other manifestations.

**Rickettsioses**

*Rickettsia* are obligately intracellular bacteria with a gram negative cell wall and a characteristic lipopolysaccharide. Their main target is the microvascular endothelium and different cells in their arthropod host/vector (fleas, ticks, lice, mites). Spotted fever group rickettsiae (with the exception of *Rickettsia felis* [fleas] and *Rickettsia akari* [mites]) are transmitted transovarially and transstadially in their tick vector and circulate in nature via small mammals. Fleas and lice host typhus group rickettsiae although they do not transmit the infection vertically to their offspring.

Newly described rickettsioses include *Rickettsia africae* (African tick bite fever), a closely related agent named *Rickettsia parkeri* (clusters of a relatively mild febrile disease in North and South America), *Rickettsia slovaca* (tick-borne lymphadenopathy or DEBONEL [Dermacentor-borne necrosis, eschar, lymphadenopathy]), *R. felis* (flea-borne spotted fever), *Rickettsia honei* ([Flinders Island spotted fever], and *Rickettsia japonica* (Japanese spotted fever)). The geographic distribution of these agents continues to expand. In fact, the distribution of organisms that appear to be variants of *R. japonica* now includes China and Korea. *R. honei* has been described in Thailand, and *R. felis* is probably distributed worldwide.

**Ehrlichioses and Anaplasmosis**

Obligately intracellular bacteria in the family *Anaplasmataceae*, which are related to the genus *Rickettsia*, include four human pathogens, *Ehrlichia chaffeensis* (human monocytotropic ehrlichiosis, HME), *Anaplasma phagocytophilum* (human granulocytotropic anaplasmosis, HGA), *Ehrlichia ewingii* (ehrlichiosis ewingii), and *Neorickettsia sennetsu* (mononucleosis-like illness in Japan). *N. sennetsu* is limited geographically to Japan, and its tick vector host cycle differs greatly from the other pathogens in this family. The other three agents are tick-borne and have been considered until recently as veterinary pathogens. HME was first described in 1987, followed by HGA in 1994 and ehrlichiosis ewingii in 1999.

HME is predominantly transmitted by *Amblyomma americanum* ticks, and its main mammal reservoir in nature is the white-tailed deer (*Odocoileus virginianus*). Patients develop a febrile illness after a nymphal or
adult tick bite accompanied by headache, myalgias, malaise, and other nonspecific symptoms. A maculopapular skin rash is present in only 30–40% of cases. Common laboratory findings are the presence of leukopenia and/or thrombocytopenia during the acute phase of the disease. Complications include meningooencephalitis, hepatitis, and diffuse alveolar damage.

HGA is transmitted by *I. scapularis* ticks in the eastern United States and *I. ricinus* in Europe. The clinical picture is similar to HME although the case-fatality ratio and complications are less severe. The target cell of *A. phagocytophilum* is the polymorphonuclear neutrophil as compared with monocytes and macrophages for *E. chaffeensis*. The main reservoir in the eastern United States is the white footed mouse.

Ehrlichiosis ewingii caused by *E. ewingii* is the least known of the human ehrlichioses. It is transmitted by the same vector tick as *E. chaffeensis* and has a milder course. The target cell is the neutrophil. The majority of cases have been diagnosed in immunocompromised patients.

**Scrub Typhus**

A disease that ravaged American troops in the Pacific and Southeastern Asia during World War II is re-emerging in southern India, Sri Lanka, the Maldives, and Micronesia. The agent is *Orientia tsutsugamushi*, an obligately intracellular bacterium formerly known as *Rickettsia tsutsugamushi*. The disease is transmitted by chiggers in their larval stage and occurs mostly in tropical Asia, the western Pacific islands, northern Australia, and temperate zones in Kashmir, Korea, Japan, and the lower Himalayas. In nature, wild rats maintain the chigger population (*Leptotrombidium* spp.), and *Orientia* is transmitted transovarially and transstadially. However, rats are not reservoirs for *O. tsutsugamushi*.

The disease is characterized by fever, headache, malaise, and a variable incidence of eschar formation at the bite site, lymphadenopathy, and a transient maculopapular rash. Severe manifestations include diffuse alveolar damage and meningooencephalitis. Poor responses to conventional treatments (tetracyclines and chloramphenicol) have been described in Thailand.

**Bartonelloses**

The genus *Bartonella* contains five recognized human pathogens: *B. bacilliformis* (Oroya fever and verruga peruana transmitted by sandflies of the genus *Lutzomyia*), *B. quintana* (trench fever, bacillary angiomatosis, and endocarditis transmitted by the human body louse, *Pediculus humanus corporis*), *B. henselae* (cat scratch disease, bacillary angiomatosis, and endocarditis transmitted by cat fleas and cats), and *B. elizabethae* and *B. vinsonii* (endocarditis, transmitted possibly by fleas and ticks).

The reservoir host for *B. bacilliformis* is humans who reside in endemic areas in Peru, Ecuador, and Colombia. Clinically the disease has an acute phase in which the main manifestation is severe hemolytic anemia followed by a chronic phase in which lesions composed of prominent capillary proliferations are present on the skin.

Trench fever affected millions of soldiers during World Wars I and II, and infections continue to be diagnosed worldwide especially in patients with HIV or malnourished, homeless alcoholics.

The feline ectoparasite flea *Ctenocephalides felis* is the vector of *B. henselae*, and humans acquire infection from contact with flea-infested cats. Endocarditis is a serious form of infection that can occur with *B. quintana*, *B. henselae*, *B. elizabethae*, and *B. vinsonii*. The epidemiology of the latter two infections is largely unknown.

**EMERGING ENTERIC PATHOGENS**

**Cholera**

*Vibrio* spp. are gram negative, oxidase positive, free-living bacteria found in warm, salty waters around the world. In these places, *Vibrio* is usually isolated from shellfish, and their concentration in the tissue is far greater than in the surrounding waters. *Vibrio cholerae*, *Vibrio vulnificus*, and *Vibrio parahaemolyticus* are all associated with acute enteric infections in humans although the only one causing epidemics or pandemics is *V. cholerae*. The latter two are also associated with wound infections in warm salty waters or ingestion of raw shellfish with involvement of subcutaneous tissue and skeletal muscle and septicemia. Infections caused by *V. parahaemolyticus* and *V. vulnificus* are more severe in immunocompromised patients and in persons with underlying diseases such as cirrhosis, hemochromatosis, and diabetes.

*V. cholerae* is classified by O antigens (>150), biotypes (classical and El Tor), and serotypes (Ogawa, Inaba). Six of the seven pandemics since the 19th century have originated in the Bengal basin, and the seventh pandemic began in 1961 in Indonesia. In 1991 this pandemic extended to Peru and other countries on the South American Pacific coast. In the US, the rare cholera cases have been linked to consumption of raw oysters or undercooked crab. All cases of *V. cholerae* infection were caused by O1 strains, but since
1992, 0139 strain has been isolated from clinical cases of cholera in the Indian subcontinent. Other non-O1 serogroups are sporadically associated with acute gastroenteritis around the world.

The majority of people infected with V. cholerae are asymptomatic or mildly ill (75% for the classical biotype and 93% for El Tor biotype). Presentation of the classic illness is explosive after a short incubation period (12h–5 days) and consists of abundant watery diarrhea that leads to dehydration and circulatory collapse if not treated promptly.

**Nontyphoidal Salmonelloses**

In the United States, infections caused by nontyphoidal *Salmonella* spp. affect 1.4 million/year and kill approximately 600/year. Most patients are mildly symptomatic or asymptomatic. *Salmonella* are gram-negative bacilli, nonlactose fermentors. The classification and nomenclature are extremely complex, but phylogenetic studies based on DNA sequencing reveal that *Salmonella* spp. associated with human illness are considered *Salmonella choleraesuis*, which has approximately 2500 serotypes including Typhimurium and Typhi. The name *Salmonella enterica* has been proposed to replace *S. choleraesuis*.

Virtually all cases of *Salmonella* infection are foodborne and are second only to enteric infections caused by *Campylobacter* spp. in the US. Foods associated with outbreaks in the US include undercooked ground beef, eggs, cheese, ice cream, fresh sprouts, juice, and other vegetables.

Clinical syndromes in nontyphoidal salmonellosis include gastroenteritis, bacteremia/septicemia with or without distant focal infections (infectious endarteritis in arteries with large atherosclerotic plaques, septic arthritis, and endocarditis) and asymptomatic carriage. Patients with immunosuppression of any etiology are at greater risk for systemic illness than immunocompetent patients.

Antimicrobial resistance (ampicillin, tetracyclines, chloramphenicol, streptomycin, and sulfonamides) in nontyphoidal salmonellosis is spreading throughout the world due to a specific phage infecting *Salmonella* type Typhimurium (DT104) that first appeared in 1990. Even more recently, resistance to fluoroquinolones and third and fourth generation cephalosporins has been reported.

**Shiga-toxin Producing Escherichia coli Infection**

The first human cases due to this organism were described in 1982 during two outbreaks of hemorrhagic colitis in the US due to *E. coli* serotype O157:H7. The association of hemorrhagic gastroenteritis due to O157:H7 and hemolytic uremic syndrome (microangiopathic hemolytic anemia, acute renal failure, and thrombocytopenia) was established soon thereafter. More than 30 serotypes of *E. coli* can produce Shigella-like toxins, but the vast majority of cases in the US are due to serotype O157:H7. The main vehicles of transmission are contaminated food (hamburgers, uncooked vegetables, and others), water, including swimming pools, person-to-person, and animal contacts.

Clinical presentation is rapid and includes vomiting, diarrhea, and cramping. The diarrhea becomes blood-streaked after a few days. One of the main complications is hemolytic uremic syndrome, mostly in patients under 5 years of age.

**Helicobacter pylori Infection**

The isolation of *H. pylori* (initially classified as *Campylobacter pylori* or *pyloridis*) from a human with active gastritis represents a turning point in how the medical field views peptic ulcer disease, acute and chronic gastritis, and gastric carcinoma (especially the intestinal variant). *H. pylori* is a motile, microaerophilic, gram-negative bacillus capable of surviving in the harsh environment of the human stomach due to its microaerophilicity, capacity to penetrate the mucus layer overlying the gastric mucosa, and production of ammonia from urea via urease to neutralize the low pH in the environment. *H. pylori* infections seem to be limited to humans, but other *Helicobacter* spp. have been isolated from almost every mammal studied. Rates of infection in human populations are very high (in developing countries up to 70% by age 10 and nearly 100% by age 20), but clinical disease is not always apparent. Therefore, microbial and host factors are important in pathogenicity. The so-called cag pathogenicity island, the vacA gene, and their polymorphisms seem to play important roles in pathogenesis.

Human infections have been present for thousands of years based on studies of *H. pylori* alleles and human migrations. Once infection is acquired it persists for years or decades. Clinical syndromes associated with *H. pylori* infection include chronic diffuse superficial gastritis, intestinal metaplasia and atrophic gastritis, peptic, especially duodenal, ulcers (cagA-containing organisms), noncardiac gastric adenocarcinoma (cagA-containing bacteria), and gastric MALT-type B-cell lymphomas.

**Cryptosporidiosis**

*Cryptosporidium parvum* is a protozoan in the phylum Apicomplexa, class Sporozoa, subclass Coccidia.

I. BIOTHREATS AND EMERGING INFECTIOUS DISEASES
Recent molecular studies have shown that *C. parvum* (the species thought to cause most human infections) contains various genotypes. In humans two genotypes cause infection: bovine and human genotypes. The name *Cryptosporidium hominis* has been proposed for the human genotype. The first human case was described in 1976, and the first outbreak of cryptosporidiosis in the US was documented in 1987 in Carroll County, GA where an estimated 13,000 cases of gastroenteritis were diagnosed. The largest reported outbreak occurred in Milwaukee, WI where there were an estimated 403,000 cases in 1993. *Cryptosporidium* has been described throughout the world. Infection occurs via the fecal–oral route mostly by ingestion of contaminated water. The infectious thick walled oocysts are resistant to chlorination and survive in moist environments for long periods of time. The cycle is completed in the same host, and multiplication is both sexual and asexual. Once inside the host, *Cryptosporidium* organisms invade the microvillus surface of the epithelial cells in the terminal ileum and proximal colon leading to self-limited watery diarrhea in immunocompetent patients and chronic/persistent diarrhea in immunocompromised patients (especially with AIDS).

**Microsporidiosis**

Phylum Microsporidia are spore-forming, obligate intracellular protozoans that reside in the intestine, liver, kidneys, brain, and other tissues of wild and domesticated mammals and several other animal species. Eight genera out of more than 144 (containing more than 1000 species) have been documented as human pathogens which include *Encephalitozoon*, *Enterocytozoon*, *Pleistophora*, *Brachiola*, *Nosema*, *Trachipleistophora*, *Vittaforma*, and *Microsporidium*. The two most common species involved in humans are *Enterocytozoon bieneusi* and *Encephalitozoon intestinalis*. Microsporidioses, in general, are rare diseases in humans that have received attention due to the increased incidence of infections present in patients with AIDS.

Clinical syndromes in immunocompetent patients consist of self-limited diarrhea, ocular infections (keratitis), and meningoencephalitis. In immunocompromised patients (especially with AIDS), persistent watery diarrhea is the most common presentation. Severe CNS infections and disseminated infections have also been described including hepatitis, peritonitis, nephritis, and pneumonia.

**Bordetella Infections**

The main human pathogens in this group are *B. pertussis* (agent of whooping cough) and *B. parapertussis* (the agent of a milder form of whooping cough). Pertussis continues to be a public health problem worldwide with millions of cases reported every year. In the United States approximately 8000 cases occurred in 2002, affecting mostly adolescents and young adults. The disease seems to be largely under-diagnosed in these population groups, who are more susceptible than children because of lack of booster immunization for pertussis beyond childhood. Pertussis starts as an upper respiratory tract infection that progresses in a few days to paroxysmal cough that lasts for weeks or months. The bacterium is not invasive and remains in the respiratory tract. Secondary infections in the form of bacterial pneumonia can occur. Other complications include pneumothoraces, hernias, seizures, and otitis media.
**Staphylococcus aureus Infections**

This gram positive, aerobic coccus is one of the most ubiquitous microorganisms in human populations and is responsible for a wide spectrum of human diseases that range from simple skin “boils” to life-threatening generalized infections. In the last few decades, new clinical entities associated with *S. aureus* have emerged such as staphylococcal toxic shock syndrome (STSS), which is a potentially lethal disease mediated by a “superantigen” toxin (TSST-1) and is characterized by fever, hypotension, multisystem organ failure, and an erythematous rash that desquamates during recovery. TSST-1 is a nonspecific T-cell mitogen that leads to a dramatic increase of T-cells and subsequent increase in circulating cytokines. This syndrome was initially described in the setting of vaginal colonization by toxin-producing strains and use of superabsorbent tampons in 1978. This type of tampon was withdrawn from the market, and the incidence declined. However, nonmenstrual forms do exist and are associated with nasal packing, surgical wounds, and other focal *S. aureus* infections. A related condition present in neonates has been described recently in Japan and is known as neonatal toxic shock syndrome-like exanthematous disease.

Antibiotic resistance is a major problem in nosocomial infections due to *S. aureus*. Both methicillin-resistant and glycopeptide-resistant strains are a major threat in the hospital setting. *S. aureus* may be part of the normal flora, especially of the nares and skin. Other sites include the genitourinary tract, mucous membranes, GI tract, and upper respiratory tract. In fact, most infections are considered to be endogenous in origin.

Coagulase negative *Staphylococci* have also emerged as human pathogens in the setting of indwelling catheters and bioprosthetic devices. These bacteria are capable of forming extensive biofilms on inert surfaces leading to local or systemic infections.

**Streptococcus pyogenes Infections**

This complex group of bacterial pathogens is responsible for a wide spectrum of infections in humans ranging from focal infections such as acute tonsillitis to the highly lethal streptococcal necrotizing fasciitis (better known as flesh-eating disease). The classification of *S. pyogenes* is based on antigenic properties and presence or absence of hemolysis on blood agar plates.

Classical diseases caused by this group of streptococci include its nonsuppurative complications (acute rheumatic fever and glomerulonephritis), tonsillitis, and scarlet fever. During the last two decades, GABHS have been associated with severe necrotizing fasciitis or streptococcal gangrene and streptococcal toxic shock syndrome. These conditions are associated with highly virulent streptococci capable of producing toxin superantigens (streptococcal pyrogenic exotoxins, SPE-A, SPE-B, and SPE-C) and other virulence factors capable of destroying host tissues. Fortunately, antibiotic resistance is not a major concern in infections caused by GABHS since the strains are still susceptible to most penicillin-related antibiotics. However, resistance to clindamycin and macrolides has been documented. Similar to *Staphylococci*, these organisms are part of the normal flora of multiple body sites including the skin, vagina, and pharynx.

**Streptococcus agalactiae Infections**

Group B streptococcal (*S. agalactiae*) infections have also emerged as a major cause of neonatal sepsis related to carriage of the bacterium in the vagina of pregnant women. Other conditions include focal and generalized infections in nonpregnant adults. Underlying conditions usually present in these patients are diabetes mellitus, neoplastic diseases, immobility, and chronic liver disease.

**EMERGING CHRONIC VIRAL DISEASES**

**Acquired Immunodeficiency Syndrome**

A pathogenic retrovirus infecting one of the most important cells orchestrating the acquired immune response in humans was something no scientist had in mind at the beginning of the 1980s. We now know that human immunodeficiency virus (HIV) infections were probably occurring sporadically for decades before the initial cases of HIV infection/AIDS were documented in the early 1980s. Unfortunately, HIV infection turns out to be one of the worst epidemics in modern history with more than 42 million people currently infected, most of whom live in sub-Saharan Africa (cumulative...
number of cases since the epidemic began is approximately 70 million). AIDS has already claimed at least 25 million deaths around the world, and although major therapeutic advances have been made, the possibility of a vaccine or a cure remains elusive.

An evolving problem within the HIV emergence as a pathogen is viral resistance to antiretroviral drug therapy. Due to the high rates of recombination and mutation in HIV genes, drug resistance is very common in patients receiving only one anti-HIV medication. Therefore, treatment regimens usually employ multiple medications. Even so, development of resistance still occurs. Rates of resistant infections vary from 3 to 4% in Australia to 23% in some areas of the United States.

HIV infection is transmitted sexually, through exposure to infected blood (intravenous drug use and accidental exposures) or vertically from mother to fetus. Virus gains access to target cells via the interaction of viral glycoprotein gp120 and the cellular receptor CD4 and chemokine receptor CCR5, both present in macrophages and CD4+ T-cells. During the acute infection some patients develop a flu-like illness that is in some cases accompanied by a maculopapular rash. Viremia is then reduced dramatically after a few weeks by both neutralizing antibody and cytotoxic T-cells. A variable latency period then ensues and ranges from years to decades during which there is progressive deterioration of the immune system due to declining levels of CD4+ T-cells. As the population of CD4+ T-cells declines, the occurrence of opportunistic infections and certain neoplasm increases, marking the appearance of AIDS per se.

HIV-2

This virus entered human populations more recently than HIV-1 and came directly most likely from sooty mangabeys. The virus is most prevalent in west Africa. Transmission from such animals probably occurs through bites and scratches or contact with infected tissues by hunters. Viremic levels in patients with HIV-2 infections are lower than HIV-1 patients, and the proportion of nonprogressers is higher.

HTLV-I and II

HTLV-I was isolated from a patient with a T-cell leukemia/lymphoma and was the first human retrovirus that was associated with human neoplasia. A few years later, HTLV-II was isolated from a patient with hairy cell leukemia, an association that has not been observed subsequently. HTLV-I is endemic in Japan (Okinawa), East Asia, Papua New Guinea, and the Caribbean basin. Routes of infection include sexual intercourse, vertical transmission from mothers to offspring, blood transfusions, and use of contaminated needles. Typically, patients with adult T-cell lymphoma/leukemia have hypercalcemia. Tropical spastic paraparesis (Caribbean) and HTLV-associated myelopathy (Japan) are associated with both HTLV-I and HTLV-II.

Human Herpesvirus (HHV) Infections

These agents are large, enveloped, double-stranded DNA viruses that infect a wide variety of species. So far, eight herpesviruses have been associated with human illness, namely herpes simplex viruses I and II (HHV1 and 2, respectively), varicella-zoster virus (HHV3), Epstein–Barr virus (EBV or HHV4), cytomegalovirus (CMV or HHV5), human herpesvirus 6 (HHV6), human herpesvirus 7 (HHV7), and Kaposi sarcoma virus (HHV8). The common denominator for all human herpesvirus infections is lifelong latent infection. Clinical syndromes are varied. The main pathogenic mechanisms include direct cytotoxicity, immunopathologic responses, and neoplastic transformation of host cells (HHV4 and HHV8).

Hepatotropic Viruses

Well-defined viral pathogens causing acute and chronic hepatitis belong to different families including hepatitis A (Picornaviridae), hepatitis B (Hepadnaviridae), hepatitis C (Flaviviridae), and hepatitis E (Hepeviridae).

Hepatitis A is transmitted by the fecal–oral route and is a common cause of acute hepatitis in developing countries. Chronicity does not occur, and most patients recover from acute infections. In fact, the majority of patients are anicteric during the acute infection. An effective parenteral vaccine is currently available.

Hepatitis B virus currently infects more than 500 million people worldwide with the highest incidence in the Far East. Routes of transmission are varied and include vertical (prenatal and perinatal) and horizontal (unprotected sex, intravenous drug use, exposure to contaminated fluids and blood products). Infection in humans ranges from asymptomatic carriers to late complications including cirrhosis and hepatocellular carcinoma. In between, patients can develop acute and chronic hepatitis. Some patients develop extrahepatic manifestations, which are immune-mediated including glomerulonephritic syndromes, vasculitides, and
polyarthritis. An effective vaccine is available and has controlled the incidence and prevalence of hepatitis B infections in the industrialized world.

Hepatitis delta virus (HDV) is a satellite virus known as delta (δ) hepatitis virus that requires hepatitis B virus to complete its life cycle in the eukaryotic host cell. HDV replication needs HBsAg for packaging of the HDV genome. The exact classification of the virus remains elusive, but it is related to viroids, plant satellite viruses, and simple infectious RNA molecules. The current classification is that of Deltaviridae family. Infection with HDV occurs either as a co-infection with HBV or a superinfection in a patient already infected with HBV. When both viruses are present, the risk of severe disease is fourfold when compared to patients infected with HBV alone. The spectrum of disease ranges from asymptomatic to end-stage liver disease (cirrhosis). In addition, superinfected patients are at higher risk for developing fulminant acute hepatitis.

Hepatitis C virus is an enveloped, positive-stranded RNA virus that has become one of the leading causes of chronic hepatitis, cirrhosis and hepatocellular carcinoma in the world. The virus has recently been cultivated in cell lines in vitro, and animal models of infection are available. A sensitive diagnostic test based on antibody detection in serum and RT-PCR detection of the viral RNA revolutionized diagnosis of hepatitis C infection during the mid- to late-1990s. Most cases develop chronicity leading in many patients to subsequent fibrosis, cirrhosis, and an increased risk of hepatocellular carcinoma. However, even among patients with chronic hepatitis C viral infections, only 5–20% develop cirrhosis. Clearly, several host and viral factors are in play. Consumption of alcohol is a synergistic factor in developing complications such as cirrhosis. Other factors include viral genotype, HIV co-infection and HLA phenotypes. Transmission is through percutaneous exposure and transfusion of contaminated blood products, although the latter is rare in countries where blood products are tightly regulated. Sexual and vertical transmission is rare. Current estimates suggest that the virus has infected 170 million people worldwide and close to 4 million persons in the US.

Hepatitis E virus is responsible for enteric non-A, non-B hepatitis epidemics in developing countries (especially in Southeast and Central Asia, Middle East, and North Africa). Outbreaks have also been described in Mexico. However, infections are mostly endemic. The disease is transmitted through the fecal–oral route, and the disease is a self-limited acute hepatitis with no known chronicity. In pregnant women, the incidence of fulminant hepatitis is high. HEV is a non-enveloped, single-stranded, positive-sense RNA virus, formerly known as enterically transmitted non-A, non-B hepatitis virus. The viral genome was cloned in 1990. Morpologically, the closest related viruses are those of the family Caliciviridae. However, the genomic organization is closer to the rubella virus which is in the family Togaviridae genus Alphavirus.

I. BIOTREATS AND EMERGING INFECTIOUS DISEASES

For most potential bioterror agents such as *Bacillus anthracis*, humans are a dead-end host. However, some viruses and bacteria that are considered in the high priority categories for use in bioterrorism have the capability for establishment in the human population via person-to-person transmission or in zoonotic cycles. These diseases could spread widely geographically and affect many persons, creating public terror as the perpetrators intended. Although smallpox was eradicated nearly 30 years ago, Soviet scientists in the mammoth Biopreparat program weaponized variola virus and produced tons of the agent. If even a single person were infected with smallpox by a terrorist, there would be the potential for widespread transmission around the world where vaccination ceased decades ago. The outcome of re-establishment of a viral agent that is transmitted from person-to-person by aerosol and small droplet spread is evident in the reintroduction of influenzavirus A H1N1, the origin of which some sources attribute to release from a Russian laboratory. This virus that had ceased to circulate after the H2N2 influenzavirus A pandemic in the late 1950s is now co-circulating with the 1968 pandemic H3N2 influenzavirus A. Intentional release of agents capable of person-to-person transmission could result in their emergence or re-emergence.

The potential for establishment of an agent introduced into widely geographically dispersed zoonotic cycles from which transmission to humans occurs is exemplified by the events after the appearance of WNV in New York City in 1999. Although there is no evidence that WNV was introduced into the US by a terrorist, it could have been done, and there are other potential bioterror agents that could be brought to the US and become established in expanding zoonotic cycles. These include other mosquito-borne viruses such as RVF virus and Venezuelan equine encephalitis virus. These would threaten both domestic animals and humans. Other agents of bioterror such as foot and mouth disease virus or *Ehrlichia ruminantium* could target our food animals and ruin our livestock.
industry. Food and mouth disease and heartwater do not occur in the US, and their establishment would be catastrophic, particularly if wild ruminants became reservoirs of infection.

The recent occurrence of global SARS and domestic monkeypox epidemics demonstrate the capacity of EIDs to be used in the future for bioterrorism. These viruses exist in natural cycles in Southeast Asia and Central and West Africa, respectively. SARS-coronavirus is a particularly serious threat because of person-to-person spread and significant mortality. Strains of monkeypox virus from Central Africa also cause significant mortality, and the danger of its intentional establishment in a wildlife reservoir such as prairie dogs would create prolonged terror. Thus, EID agents could be used for bioterrorism, and agents of bioterror could become emerging infections.

**RATIONALE FOR VACCINES AGAINST EMERGING INFECTIOUS DISEASES**

The rationale for not developing vaccines against EIDs and not developing platforms that can be rapidly applied to newly emerging infections is that apparently small problems will not grow and that what we do not know will not hurt us. The fallacies of these concepts are quite evident in the ongoing tragedy of HIV/AIDS.

Vaccines are the province of industry. The sole rationale for commercial vaccine development is profit calculated as return on investment to stockholders. A particular vaccine would have to be more profitable than a particular drug in order to have resources for development and manufacture devoted to it. Successful vaccines from the perspective of preventive medicine are given only once and induce lifelong protection, translating as a single sale per customer. Drugs for prevalent chronic diseases require enormous numbers of doses for decades. The money and effort invested in development of a vaccine that could have produced a blockbuster drug represent lost opportunity cost to the pharmaceutical enterprise. The effects of not developing more effective and safer vaccines against whooping cough and tuberculosis are measured in days of active life lost, medical costs, and deaths that are borne by society, most often in developing countries. The same metrics apply to DF, DHF, Lassa fever, louse-borne typhus, scrub typhus, leptospirosis, and Venezuelan equine encephalitis.

Other pathogens for which effective vaccine development effort should be undertaken are agents for which antibiotic resistance is a significant threat, potentially water-borne agents that are resistant to control by chlorination, and agents of veterinary diseases that would be potential agents of devastating agroterrorism. The rising problem of bacterial antimicrobial resistance is evident to all, particularly for nosocomial infection. What is generally ignored is the creation of weapons for biowarfare or bioterrorism that are resistant to antimicrobial treatment. For example, the confidence that rickettsial diseases respond well to early treatment with doxycycline should be reconsidered in light of the development of tetracycline-resistant *Rickettsia prowazekii* in a Russian laboratory. Similarly contamination of municipal...
water supplies with chlorine-resistant organisms such as *Cryptosporidium parvum* would cause severe havoc. After several widespread outbreaks, the public would be receptive to prevention by an effective vaccine.

Development of veterinary vaccines is an important goal on its own merit. The lessons that would be learned by the development of vaccines against foot and mouth disease virus, *E. ruminantium*, and *Burkholderia mallei* would have additional impact on human diseases caused by related agents. Other veterinary pathogens such as Venezuelan equine encephalitis virus, *Brucella melitensis*, *Brucella abortus*, *Brucella suis*, and RVF virus are also human disease agents.

Respiratory diseases deserve special consideration for preparation for prevention by development of vaccines. The potential reappearance of SARS-coronavirus should energize efforts to produce an effective vaccine. The threat of pandemic influenza A combines nearly every reason that could be marshaled for all agents together to create a system for rapid vaccine formulation, testing, and manufacture.

**THE CHALLENGE OF DEVELOPING VACCINES AGAINST EMERGING AND RE-EMERGING INFECTIOUS DISEASES**

The development of a new vaccine is not easy by any means. Even when the pharmaceutical industry recognizes the market potential of a vaccine against an emerging pathogen, such as HIV or hepatitis C virus, there are many difficult steps between the desire to develop the vaccine and its availability for purchase. There are more steps from the discovery of a newly EID agent to the availability of a vaccine against it than for a pathogen that has been studied for decades or more than a century. First, the pathogen must be characterized at the levels of biology, molecular composition, and its genome. Even well into the contemporary molecular, proteomic, and genomic era, knowledge of the proteome and genetic sequence provides no more complete understanding of the agent than possession of an encyclopedia, which written in a language that has been translated only partly, would impart omniscience. Second, appropriate animal models that adequately mimic the pathology of the human disease, anatomic distribution of the agent, and the human immune response to the infection must be developed. There are numerous agents that are so highly adapted to humans that no adequate animal model exists. Other models utilize animal species that do not permit effective analysis of the protective immune response owing to lack of reagents to evaluate the immune cells and proteins and absence of animals that are genetically inbred or have knockout of specific genes. Third, studies of animal models and of humans and their cells, cytokines, and antibodies are employed to elucidate the mechanisms of protective immunity. Development of a vaccine that stimulates the presence of memory cells that generate the immune components required to kill the invading pathogen rapidly requires determining which elements (e.g., antibodies, CD4, and/or CD8 T lymphocytes) are critical. Fourth, the antigens of the particular infectious agent that stimulate the protective memory immune components must be identified. For subunit vaccines, some antigens stimulate protective responses, and others suppress protective immunity. Fifth, the animal models are utilized to develop and test vaccine candidates that stimulate protective memory immune responses without harmful side effects. At the point of the primary identification of the etiology of the emerging infection, it would be unlikely that any of these five steps would have been addressed.

Because many emerging infections are zoonotic diseases that have naturally occurring animal counterparts, a strategy of developing related veterinary vaccines on the pathway toward future development of a vaccine for humans may be feasible owing to financial and regulatory considerations. Imagine how much better off we would be today if an effective vaccine against a simian immunodeficiency virus had been produced in the 1970s or a changeable molecular cassette subunit vaccine had been approved for avian influenza viruses a decade ago. The crucial message regarding vaccines for emerging infections diseases is that it is never too early to support research to achieve the five steps outlined above.

**Suggested Reading**


I. BIOTHREATS AND EMERGING INFECTIOUS DISEASES

I. BIOTHREATS AND EMERGING INFECTIOUS DISEASES
ABSTRACT

A range of bacterial pathogens might be used illegitimately to cause disease in humans or animals. The properties of these pathogens are dissimilar. Much of our information on the properties of these pathogens comes from past programs to develop biological weapons. In principle, disease caused by bacterial biothreat agents could be prevented or treated using antibiotics. However, there are limitations associated with the use of antibiotics in this way. Against this background vaccines will play a key role in protecting vulnerable populations from bacterial biothreats.

INTRODUCTION

One simple definition of a bacterial biothreat agent is a bacterium that is used to deliberately cause disease in human, animal, or plant populations to the economic or social detriment of the host nation. Based on this type of definition there are a number of published lists of bacterial biothreat agents, ranging from those that inform export controls, such as the Australia group list, to those compiled to protect the U.S. Agricultural industry from disruption (Table 2.1). The differences in threat agents of concern reflect the difficulties in devising a single definitive list of biothreat agents. For example, agents that are likely to cause disruption of the agricultural industry are not necessarily those which would be used against a human population. Similarly, agents which would be used against civilian populations would not necessarily be used to attack the armed forces.

Despite these differences, there are some agents that consistently appear on all of the lists. The observation